London – – October 07, 2026 -- The global cold plasma in healthcare market is projected to climb from $2,873 million in 2025 to $6,634 million by 2032, a compound annual growth rate of 12.7%, according to a new report from Credence Research Inc.
Devices dominate revenue while consumables build recurring streams
Devices accounted for 68.4% of product-segment revenue in 2025, reflecting continued emphasis on installed treatment capacity ahead of scaling consumables and service income. Plasma Jet technology held 39.6% of the technology segment, while Atmospheric Pressure Cold Plasma captured 66.8% of the pressure-type category, favored for bedside and outpatient use without vacuum infrastructure.
Wound care leads clinical applications with 28.9% share
Wound Healing and Chronic Wound Management ranked as the top application category, supported by repeat-treatment protocols and demand for non-thermal microbial control. Hospitals represented 41.7% of end-user demand in 2025, though outpatient and specialty clinics are emerging as expansion channels given the portability of atmospheric-pressure systems.
North America leads regional adoption at 38.9% share
North America held the largest regional share in 2025 at 38.9%, followed by Europe at 31.2% and Asia Pacific at 21.0%. The report attributes regional variance to differences in clinical evidence, regulatory approval pathways and service infrastructure availability.
Suppliers expand through partnerships and distribution deals
In February 2025, Royal Wound-X, a division of Royal Biologics, partnered with Coldplasmatech GmbH on complex and chronic wound care using Cold Atmospheric Plasma technology. In April 2025, Viromed Medical AG signed an exclusive distribution agreement with UMECO Group to commercialize its ViroCAP and PulmoPlas devices across ten Asian markets. In June 2025, neoplas med launched its Argon Cold Plasma Jet kINPen MED in Muscat, Oman, at an event attended by public and private healthcare professionals.
Procurement scrutiny and evidence gaps temper adoption pace
Capital equipment purchases compete with other hospital budget priorities, placing weight on total cost of ownership, staff training and local service coverage. Clinical evidence remains stronger in established wound-care applications than in emerging uses such as oncology, implant surface functionalization and plasma-activated liquids, creating divergent adoption timelines across the segmentation. Regulatory approvals and indicated uses also vary by device and jurisdiction, requiring suppliers to align commercialization claims with local clinical protocols.
Key players named in competitive analysis
The report identifies terraplasma medical GmbH, neoplas med GmbH, Plasmacure B.V., Coldplasmatech GmbH, Adtec Healthcare/Adtec Plasma Technology, Viromed Medical AG and relyon plasma GmbH as active suppliers in the medically relevant cold-plasma segment.